Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy [0.03%]
评估Blinatumomab治疗复发/难治性急性淋巴细胞白血病的效果：设计、开发和治疗方法的选择地位
Audrey M Sigmund,Kieran D Sahasrabudhe,Bhavana Bhatnagar
Audrey M Sigmund
Although adults with B-cell acute lymphoblastic leukemia (B-ALL) achieve high complete remission (CR) rates following treatment with intensive multi-agent chemotherapy regimens, up to two-thirds of these patients eventually relapse. Unfortu...
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy [0.03%]
年龄对接受伊布替尼作为初始治疗的CLL患者生存率的影响
Chaitra Ujjani,Anthony Mato,Brian T Hill et al.
Chaitra Ujjani et al.
Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reporte...
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma [0.03%]
Venetoclax在慢性淋巴细胞白血病和小淋巴细胞淋巴瘤中的作用扩大
Michael Schieber,Shuo Ma
Michael Schieber
The BCL-2 protein family members inhibit cellular apoptosis, and their overexpression represents a common survival adaption in cancer. Recently, a selective BCL-2 inhibitor ABT-199, venetoclax, has demonstrated remarkable activity in relaps...
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma [0.03%]
布伦妥欣在经典型霍奇金淋巴瘤中的应用及其地位变迁
Catherine Lai,Adrese Michael Kandahari,Chaitra Ujjani
Catherine Lai
The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreate...
Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1 [0.03%]
CRISPR/Cas9敲除BIRC5基因诱导HL-60和KG-1白血病细胞株凋亡及抑制增殖
Manizheh Narimani,Mohammadreza Sharifi,Ali Jalili
Manizheh Narimani
Introduction: Human Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) which encodes survivin exhibits multiple biological activities, such as cell proliferation and apoptosis. Survivin is overexpressed in num...
Giovanna Carrà,Antonio Cartellà,Beatrice Maffeo et al.
Giovanna Carrà et al.
Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development ...
Giacomo Andreani,Daniela Cilloni
Giacomo Andreani
Currently, the post-remission treatment in acute leukemia is based on the genetic profile of leukemic cells at diagnosis (ie, FLT3 ITD positivity) and on the level of measurable residual disease (MRD) after induction and consolidation chemo...
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens [0.03%]
CD5在双打击弥漫大B细胞淋巴瘤中的预后价值及其DA-EPOCH-R/R-CHOP疗效比较研究
Fangwen Zhang,Ling Li,Lei Zhang et al.
Fangwen Zhang et al.
Objectives: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH-R) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine and ...
IDH1-mutated relapsed or refractory AML: current challenges and future prospects [0.03%]
IDH1突变的复发或难治性AML：当前挑战与未来前景
Juan Eduardo Megías-Vericat,Octavio Ballesta-López,Eva Barragán et al.
Juan Eduardo Megías-Vericat et al.
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 (IDH1 mut ), present in 7-14% of AML patients, have been discov...
Andres Lopez,Pau Abrisqueta
Andres Lopez
Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy with large neoplastic cells, most of them resembling plasmablasts that have a CD20-negative phenotype. Although initially described as being associated with HIV, over t...